

# Meenu Wadhwa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3511492/publications.pdf>

Version: 2024-02-01

89  
papers

2,719  
citations

270111

25  
h-index

214428

50  
g-index

90  
all docs

90  
docs citations

90  
times ranked

3316  
citing authors

#	ARTICLE	IF	CITATIONS
1	Protein Engineering and HDX Identify Structural Regions of G-CSF Critical to Its Stability and Aggregation. <i>Molecular Pharmaceutics</i> , 2022, 19, 616-629.	2.3	4
2	WHO informal consultation on revision of guidelines on evaluation of similar biotherapeutic products, virtual meeting, 30 June – 2 July 2021. <i>Biologicals</i> , 2022, 76, 1-9.	0.5	2
3	2021 White Paper on Recent Issues in Bioanalysis: ISR for Biomarkers, Liquid Biopsies, Spectral Cytometry, Inhalation/Oral & Multispecific Biotherapeutics, Accuracy/LLOQ for Flow Cytometry (<u>Part 2</u> – Recommendations on Biomarkers/CDx Assays Development & Validation,) <i>TJ ETQq1 1 0.7843 14 rgBT/Overlock</i>	0.6	14
4	2021 White Paper on Recent Issues in Bioanalysis: Mass Spec of Proteins, Extracellular Vesicles, CRISPR, Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Rare Matrices; Regulatory Inputs (<u>Part 1A</u> – Recommendations on Endogenous Compounds, Small Molecules,) <i>Tj ETQq0 0 0 rgBT/Overlock</i>	0.6	14
5	2021 White Paper on Recent Issues in Bioanalysis: TAB/INAb, Viral Vector CDx, Shedding Assays; CRISPR/Cas9 & CAR-T Immunogenicity; PCR & Vaccine Assay Performance; ADA Assay Comparability & Cut Point Appropriateness (<u>Part 3</u> – Recommendations on Gene Therapy,) <i>Tj ETQq0.6 0.7843 14 rgBT/Overlock</i>	0.6	14
6	Regulatory challenges with biosimilars: an update from 20 countries. <i>Annals of the New York Academy of Sciences</i> , 2021, 1491, 42-59.	1.8	20
7	Maintaining “standards”™ for biosimilar monoclonal antibodies. <i>Nature Biotechnology</i> , 2021, 39, 276-280.	9.4	12
8	The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring. <i>Frontiers in Immunology</i> , 2021, 12, 636420.	2.2	7
9	Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19. <i>Biomedicine and Pharmacotherapy</i> , 2021, 140, 111785.	2.5	14
10	The First WHO International Standard for Harmonizing the Biological Activity of Bevacizumab. <i>Biomolecules</i> , 2021, 11, 1610.	1.8	2
11	WHO International Standards and Reference Preparations for Cytokines and Growth Factors. <i>Journal of Leukocyte Biology</i> , 2020, 107, 159-160.	1.5	0
12	Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs. <i>AAPS Journal</i> , 2020, 22, 7.	2.2	17
13	WHO implementation workshop on guidelines on procedures and data requirements for changes to approved biotherapeutic products, Seoul, Republic of Korea, 25–26 June 2019. <i>Biologicals</i> , 2020, 65, 50-59.	0.5	1
14	The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019. <i>Biologicals</i> , 2020, 65, 1-9.	0.5	34
15	Harmonization and standardization of immunogenicity assessment of biotherapeutic products. <i>Bioanalysis</i> , 2019, 11, 1593-1604.	0.6	8
16	Bioanalytical strategies in determining immunogenicity. <i>Bioanalysis</i> , 2019, 11, 1535-1537.	0.6	0
17	The impact of thioredoxin reduction of allosteric disulfide bonds on the therapeutic potential of monoclonal antibodies. <i>Journal of Biological Chemistry</i> , 2019, 294, 19616-19634.	1.6	10
18	The first World Health Organization International Standard for infliximab products: A step towards maintaining harmonized biological activity. <i>MABs</i> , 2019, 11, 13-25.	2.6	16

#	ARTICLE	IF	CITATIONS
19	Endothelial cell functions impaired by interferon in vitro: Insights into the molecular mechanism of thrombotic microangiopathy associated with interferon therapy. <i>Thrombosis Research</i> , 2018, 163, 105-116.	0.8	41
20	WHO informal consultation on development of guidelines on procedures and data requirements for changes to approved biotherapeutic products, Seoul, Republic of Korea, 27-28 April 2017. <i>Biologicals</i> , 2018, 52, 83-91.	0.5	2
21	2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2 - PK, PD & ADA assays by hybrid LBA/LCMS & regulatory) <i>Trends in Analytical Chemistry</i> , 2018, 107, 1-14.	0.8	14
22	2018 White Paper on Recent Issues in Bioanalysis: focus on flow cytometry, gene therapy, cut points and key clarifications on BAV (Part 3 - LBA/cell-based assays: immunogenicity, biomarkers and PK) <i>Trends in Analytical Chemistry</i> , 2018, 107, 15-24.	0.8	14
23	Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab. <i>Cytokine</i> , 2017, 96, 16-23.	1.4	24
24	Surrogate CD16-expressing effector cell lines for determining the bioactivity of therapeutic monoclonal antibodies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 143, 188-198.	1.4	6
25	Establishment of the first WHO International Standard for etanercept, a TNF receptor II Fc fusion protein: Report of an international collaborative study. <i>Journal of Immunological Methods</i> , 2017, 447, 14-22.	0.6	11
26	Influence of <i>Escherichia coli</i> chaperone DnaK on protein immunogenicity. <i>Immunology</i> , 2017, 150, 343-355.	2.0	18
27	IL-27 Promotes Proliferation of Human Leukemic Cell Lines Through the MAPK/ERK Signaling Pathway and Suppresses Sensitivity to Chemotherapeutic Drugs. <i>Journal of Interferon and Cytokine Research</i> , 2016, 36, 302-316.	0.5	25
28	Editor's Highlight: Subvisible Aggregates of Immunogenic Proteins Promote a Th1-Type Response. <i>Toxicological Sciences</i> , 2016, 153, 258-270.	1.4	33
29	Establishment of the first WHO Erythropoietin antibody reference panel: Report of an international collaborative study. <i>Journal of Immunological Methods</i> , 2016, 435, 32-42.	0.6	9
30	Quality and Batch-to-Batch Consistency of Original and Biosimilar Epoetin Products. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 542-550.	1.6	18
31	Establishment of the first international standard for PEGylated granulocyte colony stimulating factor (PEG-G-CSF): Report of an international collaborative study. <i>Journal of Immunological Methods</i> , 2015, 416, 17-28.	0.6	12
32	Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility. <i>Biologicals</i> , 2015, 43, 298-306.	0.5	114
33	Access to safe and effective biopharmaceuticals. <i>GaBI Journal</i> , 2015, 4, 108-109.	0.4	1
34	Standardization of Human IL-29 (IFN- $\gamma$ 1): Establishment of a World Health Organization International Reference Reagent for IL-29 (IFN- $\gamma$ 1). <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 876-884.	0.5	5
35	Detection of anti-cytokine antibodies and their clinical relevance. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1029-1047.	1.3	17
36	Biosimilar monoclonal antibodies approved for use in the EU. <i>GaBI Journal</i> , 2014, 3, 9-10.	0.4	2

#	ARTICLE	IF	CITATIONS
37	Use of a Standardized MxA Protein Measurement-Based Assay for Validation of Assays for the Assessment of Neutralizing Antibodies Against Interferon- $\beta$ . Journal of Interferon and Cytokine Research, 2013, 33, 660-671.	0.5	17
38	Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release. British Journal of Clinical Pharmacology, 2013, 76, 299-315.	1.1	56
39	The 2nd International standard for Interleukin-2 (IL-2) Report of a collaborative study. Journal of Immunological Methods, 2013, 397, 1-7.	0.6	3
40	Immunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFN $\beta$ interact with the endogenous cytokine and activate complement. Clinical Immunology, 2013, 148, 177-185.	1.4	17
41	European perspective on biosimilars. Bioanalysis, 2013, 5, 521-524.	0.6	6
42	Development and characterization of a non-cell-based assay to assess the presence of neutralizing antibodies to interferon-beta in clinical samples. Journal of Immunological Methods, 2013, 395, 37-44.	0.6	15
43	Detection of neutralizing antibodies to erythropoietin by inhibition of rHuEPO-stimulated EGR1 gene expression in the UT-7/EPO cell line. Journal of Immunological Methods, 2013, 387, 191-198.	0.6	3
44	Biosimilars: what clinicians should know. Blood, 2012, 120, 5111-5117.	0.6	314
45	The 1st International standard for transforming growth factor- $\beta$ 3 (TGF- $\beta$ 3). Journal of Immunological Methods, 2012, 380, 1-9.	0.6	1
46	Freeze drying formulation using microscale and design of experiment approaches: a case study using granulocyte colony-stimulating factor. Biotechnology Letters, 2012, 34, 641-648.	1.1	14
47	An Assessment of Biological Potency and Molecular Characteristics of Different Innovator and Noninnovator Interferon-Beta Products. Journal of Interferon and Cytokine Research, 2011, 31, 383-392.	0.5	26
48	Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN1412 in culture. Cytokine, 2011, 55, 141-151.	1.4	23
49	Biosimilars—why terminology matters. Nature Biotechnology, 2011, 29, 690-693.	9.4	174
50	The 2nd International Standard for human granulocyte colony stimulating factor. Journal of Immunological Methods, 2011, 367, 63-69.	0.6	6
51	Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy. Journal of Immunological Methods, 2011, 371, 134-142.	0.6	27
52	Intended use of Reference Products & WHO International Standards/Reference Reagents in the development of Similar Biological Products (Biosimilars). Biologicals, 2011, 39, 262-265.	0.5	17
53	WHO/KFDA joint workshop on implementing WHO guidelines on evaluating similar biotherapeutic products, Seoul, Republic of Korea 24-26 August, 2010. Biologicals, 2011, 39, 349-357.	0.5	11
54	Evaluation of similar biotherapeutic products: Scientific and regulatory challenges. Biologicals, 2011, 39, 249.	0.5	1

#	ARTICLE	IF	CITATIONS
55	Treatment of colitis with a commensal gut bacterium engineered to secrete human $\text{tgf-}\beta\text{1}$ under the control of dietary xylan. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1925-1935.	0.9	83
56	Are neutralizing anti- $\text{GM-CSF}$ autoantibodies present in all healthy persons?. <i>Blood</i> , 2010, 115, 433-434.	0.6	11
57	WHO international cytokine standards and reference preparations. <i>Journal of Leukocyte Biology</i> , 2010, 88, 425-426.	1.5	1
58	Unwanted immunogenicity: lessons learned and future challenges. <i>Bioanalysis</i> , 2010, 2, 1073-1084.	0.6	27
59	Detection of neutralizing interleukin-17 antibodies in autoimmune polyendocrinopathy syndrome-1 (APS-1) patients using a novel non-cell based electrochemiluminescence assay. <i>Cytokine</i> , 2010, 50, 129-137.	1.4	14
60	World Health Organization International Cytokine Standards and Reference Preparations. <i>Journal of Interferon and Cytokine Research</i> , 2010, 30, 639-641.	0.5	1
61	A novel bioassay for B-cell activating factor (BAFF) based on expression of a BAFF-receptor ectodomain-tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-2 endodomain fusion receptor in human rhabdomyosarcoma cells. <i>Journal of Immunological Methods</i> , 2008, 337, 63-70.	0.6	6
62	Haematopoietic growth factors and their therapeutic use. <i>Thrombosis and Haemostasis</i> , 2008, 99, 863-873.	1.8	40
63	Assessment of Unwanted Immunogenicity. , 2008, , 57-73.		4
64	Haematopoietic growth factors and their therapeutic use. <i>Thrombosis and Haemostasis</i> , 2008, 99, 863-73.	1.8	15
65	“Cytokine Storm” in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics. <i>Journal of Immunology</i> , 2007, 179, 3325-3331.	0.4	311
66	Unwanted Immunogenicity: Implications for Follow-on Biologicals. <i>Drug Information Journal</i> , 2007, 41, 1-9.	0.5	10
67	Continuous delivery of human type I interferons ( $\beta\text{1}/\beta\text{2}$ ) has significant activity against acute myeloid leukemia cells in vitro and in a xenograft model. <i>Blood</i> , 2007, 109, 1244-1247.	0.6	27
68	Strategies and Assays for the Assessment of Unwanted Immunogenicity. <i>Journal of Immunotoxicology</i> , 2006, 3, 115-121.	0.9	28
69	Biological activity of interleukins-28 and -29: Comparison with type I interferons. <i>Cytokine</i> , 2005, 31, 109-118.	1.4	202
70	Problems in early diagnosis of bladder cancer in a spinal cord injury patient: Report of a case of simultaneous production of granulocyte colony stimulating factor and parathyroid hormone-related protein by squamous cell carcinoma of urinary bladder. <i>BMC Urology</i> , 2002, 2, 8.	0.6	27
71	Cytokine levels as performance indicators for white blood cell reduction of platelet concentrates. <i>Vox Sanguinis</i> , 2002, 83, 125-136.	0.7	32
72	Chemokine/Chemokine Receptor Nomenclature. <i>Journal of Interferon and Cytokine Research</i> , 2002, 22, 1067-1068.	0.5	273

#	ARTICLE	IF	CITATIONS
73	Autologous plasma activates Akt/protein kinase B and enhances basal survival and resistance to DNA damage-induced apoptosis in B-chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2001, 114, 608-615.	1.2	30
74	Cytokines in WBC-reduced apheresis PCs during storage: a comparison of two WBC-reduction methods. <i>Transfusion</i> , 2000, 40, 1118-1126.	0.8	46
75	Sustained Expression of CD154 (CD40L) and Proinflammatory Cytokine Production by Alloantigen-Stimulated Umbilical Cord Blood T Cells. <i>Journal of Immunology</i> , 2000, 164, 6206-6212.	0.4	41
76	Are cytokines in platelet concentrates responsible for febrile transfusion reactions?. <i>Transfusion Science</i> , 1997, 18, 367-371.	0.6	5
77	Cytokine Contamination of Biological Products. <i>Biologicals</i> , 1997, 25, 307-318.	0.5	0
78	IL-4 and TNF- $\alpha$ -MEDIATED PROLIFERATION OF THE HUMAN MEGAKARYOCYTIC LINE M-O7E IS REGULATED BY INDUCED AUTOCRINE PRODUCTION OF GM-CSF. <i>Cytokine</i> , 1996, 8, 900-909.	1.4	7
79	Neutralising antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy. <i>Medical Oncology</i> , 1996, 13, 161-166.	1.2	15
80	Transforming growth factor- $\beta$ 1 blocks interleukin 4 induced cell proliferation by inhibiting a protein tyrosine phosphatase essential for signal transduction. <i>Cytokine</i> , 1994, 6, 389-398.	1.4	9
81	A novel, sensitive bioassay for transforming growth factor $\beta$ 2. <i>Journal of Immunological Methods</i> , 1993, 164, 61-67.	0.6	32
82	Mechanisms of inhibition of T cell IL-2 secretion by factor VIII concentrates. <i>British Journal of Haematology</i> , 1992, 82, 575-583.	1.2	24
83	Development of immunoassays for human interleukin 3 and interleukin 4, some of which discriminate between different recombinant DNA-derived molecules. <i>Cytokine</i> , 1991, 3, 562-567.	1.4	21
84	Reconstitution of interleukin 2 with albumin for infusion. <i>Lancet</i> , The, 1990, 335, 1602-1603.	6.3	8
85	Production of polyclonal and monoclonal antibodies to human granulocyte colony-stimulating factor (GCSF) and development of immunoassays. <i>Journal of Immunological Methods</i> , 1990, 128, 211-217.	0.6	7
86	DEMONSTRATION OF CYTOKINES IN BIOLOGICAL MEDICINES PRODUCED IN MAMMALIAN CELL LINES. <i>Lancet</i> , The, 1989, 334, 1011-1012.	6.3	5
87	In vivo administration of interleukin 2 stimulates mitosis in thymus and bone marrow. <i>European Journal of Immunology</i> , 1986, 16, 1171-1174.	1.6	8
88	Interleukin 2 stimulates T cell proliferation using a calcium flux. <i>Immunology Letters</i> , 1985, 10, 297-302.	1.1	23
89	Impact of Formulation Choices on the Freeze-Drying of an Interleukin-6 Reference Material. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	1